Company: ELV
Filing Date: 2025-03-10
Form Type: 8-K
Source: 0001193125-25-050889
Chunk: 0

Company: Elevance Health, Inc.
Filing Date: 2025-03-10
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 - Regulation FD Disclosure

Officers of Elevance Health, Inc. (the “ Company”) will speak with investors over the next several weeks. During these meetings, Company officers intend to reaffirm the Company’s shareholders’ earnings guidance for full year 2025 to be $30.40 to $31.10 per diluted share, including approximately $3.75 per diluted share of net unfavorable items. Excluding these items, the Company continues to expect adjusted shareholders’ earnings to be $34.15 to $34.85 per diluted share.

In addition, the Company continues to expect 2025 year-endtotal medical enrollment to be consistent with the guidance provided in its Fourth Quarter 2024 Earnings Release, dated January 23, 2025, including expectations for Medicare Advantage membership of 2.2 to 2.25 million members.

None of the information furnished in Item 7.01 hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings.